Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Non-Current Assets (2020 - 2025)

Bolt Biotherapeutics' Other Non-Current Assets history spans 6 years, with the latest figure at $981000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets fell 38.69% year-over-year to $981000.0; the TTM value through Sep 2025 reached $981000.0, down 38.69%, while the annual FY2024 figure was $981000.0, 46.13% down from the prior year.
  • Other Non-Current Assets for Q3 2025 was $981000.0 at Bolt Biotherapeutics, up from $222000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.8 million in Q4 2023 and bottomed at $51000.0 in Q1 2025.
  • The 5-year median for Other Non-Current Assets is $1.6 million (2021), against an average of $1.2 million.
  • The largest annual shift saw Other Non-Current Assets surged 58.1% in 2024 before it tumbled 96.81% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.0 million in 2021, then skyrocketed by 53.55% to $1.6 million in 2022, then grew by 13.81% to $1.8 million in 2023, then crashed by 46.13% to $981000.0 in 2024, then changed by 0.0% to $981000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Other Non-Current Assets are $981000.0 (Q3 2025), $222000.0 (Q2 2025), and $51000.0 (Q1 2025).